Atypical behavioural effects of lorazepam: Clues to the design of novel therapies?

Pharmacology and Therapeutics

Volumn 126, Issue 1, 2010, Pages 94-108

  Giersch, Anne ^a   Boucart, Muriel ^b   Elliott, Mark ^c   Vidailhet, Pierre ^a  

^a INSERM   (France)

^b CNRS   (France)

^c NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Benzodiazepines; Cognition; GABA; Imaging; Lorazepam; Memory; Perception

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ALPIDEM; ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; CLOBAZAM; CLONAZEPAM; CLORAZEPATE; DIAZEPAM; FLUMAZENIL; FLUNITRAZEPAM; IOMAZENIL; LORAZEPAM; MIDAZOLAM; NEUROLEPTIC AGENT; OXAZEPAM; PLACEBO; SCOPOLAMINE; ZOLPIDEM;

AGITATION; ANTEROGRADE AMNESIA; ANXIETY DISORDER; ATTENTION DISTURBANCE; BRAIN ELECTROPHYSIOLOGY; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; DRUG DESIGN; DRUG EFFICACY; DRUG ERUPTION; DRUG RESEARCH; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTENSION; ISCHEMIA; MEMORY DISORDER; MENTAL FUNCTION; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RESPIRATION DEPRESSION; RESPIRATORY TRACT DISEASE; RETROGRADE AMNESIA; REVIEW; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; SOMNOLENCE; TRANQUILIZING ACTIVITY; VAGUS TONE; VISUAL IMPAIRMENT;

EID: 77649272125     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.01.004     Document Type: Review

References (175)

1. Abadie P., Rioux P., Scatton B., Zarifian E., Barré L., Patat A., et al. Central benzodiazepine receptor occupancy by zolpidem in the human brain as assessed by positron emission tomography. Eur J Pharmacol 295 (1996) 35-44
2. Agelink M.W., Majewski T.B., Andrich J., and Mueck-Weymann M. Short-term effects of intravenous benzodiazepines on autonomic neurocardiac regulation in humans: A comparison between midazolam, diazepam, and lorazepam. Crit Care Med 30 (2002) 997-1006
3. Ahveninen J., Lin F.H., Kivisaari R., Autti T., Hämäläinen M., Stufflebeam S., et al. MRI-constrained spectral imaging of benzodiazepine modulation of spontaneous neuromagnetic activity in human cortex. NeuroImage 35 (2007) 577-582
4. Alldredge B.K., Gelb A.M., Isaacs S.M., Corry M.D., Allen F., Ulrich S., et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 345 (2001) 631-637
5. Andreasen N.C. A unitary model of schizophrenia: Bleuler's "fragmented phrene" as schizencephaly. Arch Gen Psychiatry 56 (1999) 781-787
6. Appleton R., Sweeney A., Choonara I., Robson J., and Molyneux E. Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus. Dev Med Child Neurol 37 (1995) 682-688
7. Ashton C.H. Benzodiazepines - How they work and how to withdraw (2002), Churchill Livingstone, Edinburgh
8. Atack J.R. GABAA receptor subtype-selective efficacy: TPA023, an α2/ α3 selective non-sedating anxiolytic and α51A, an α5 selective cognition enhancer. CNS Neurosci Ther 14 (2008) 25-35
9. Ator N.A. Drug discrimination and drug stimulus generalization with anxiolytics. Drug Dev Res 20 (1990) 189-204
10. Ator N.A., and Griffiths R.R. Differential generalization to pentobarbital in rats trained to discriminate lorazepam, chlordiazepoxide, diazepam or triazolam. Psychopharmacology 98 (1989) 20-30
11. Ator N.A., and Griffiths R.R. Selectivity in the generalization profile in baboon trained to discriminate lorazepam: benzodiazepines, barbiturates and other sedative/anxiolytics. J Pharmacol Exp Ther 282 (1997) 1442-1457
12. Ator N.A., and Kautz M.A. Differentiating benzodiazepine- and barbiturate-like discriminative stimulus effects of lorazepam, diazepam, pentobarbital, imidazenil and zaleplon in two- versus three-lever procedures. Behav Pharmacol 11 (2000) 1-14
13. Ator N.A., Grant K.A., Purdy R.H., Paul S.M., and Griffiths R.R. Drug discrimination analysis of endogenous neuroactive steroids in rats. Eur J Pharmacol 241 (1993) 237-243
14. Augsburger M., Donzé N., Ménétrey A., Brossard C., Sporkert F., Giroud C., et al. Concentration of drugs in blood of suspected impaired drivers. Forensic Sci Int 153 (2005) 11-15
15. Ballard T.M., Knoflach F., Prinssen E., Borroni E., Vivian J.A., Basile J., et al. RO4938581, a novel cognitive enhancer acting at GABA(A) alpha5 subunit-containing receptors. Psychopharmacology 202 (2009) 207-223
16. Beckers T., Wagemans J., Boucart M., and Giersch A. Different effects of lorazepam and diazepam on perceptual integration. Vis Res 41 (2001) 2297-2303
17. Bergerbest D., Ghahremani D.G., and Gabrieli J.D.E. Neural correlates of auditory repetition priming: reduced fMRI activation in the auditory cortex. J Cogn Neurosci 16 (2004) 966-977
18. Bishop K.I., and Curran H.V. Psychopharmacological analysis of implicit and explicit memory: a study with lorazepam and the benzodiazepine antagonist flumazenil. Psychopharmacology 121 (1995) 267-278
19. Block R.I., and Berchou R. Alprazolam and lorazepam effects on memory acquisition and retrieval processes. Pharmacol Biochem Behav 20 (1984) 233-241
20. Boucart M. La reconnaissance des objets (1996), Presses Universitaires de Grenoble
21. Boucart M., Delord S., and Giersch A. The computation of contour information in complex objects. Perception 23 (1994) 399-409
22. Boucart M., de Visme P., and Wagemans J. Effect of benzodiazepine on temporal integration in object perception. Psychopharmacology 3 (2000) 249-255
23. Boucart M., Waucquier N., Michael G.A., and Libersa C. Diazepam impairs the temporal dynamic of visual attention. Exp Clin Psychopharmacol 15 (2007) 115-122
24. Bourin M. Les benzodiazépine. De la pharmacologie à la dépendance. 2d édition (1989), Ellipses
25. Bradwejn J., Shriqui C., Koszycki D., and Meterissian G. Double-blind comparison of the effects of clonazepam and lorazepam in acute mania. J Clin Psychopharmacol 10 (1990) 403-408
26. Bremner J.D., Baldwin R., Horti A., Staib L.H., Ng C.K., Tan P.Z., et al. Quantitation of benzodiazepine receptor binding with PET [11C] iomazenil and SPECT [123I] iomazenil: Preliminary results of a direct comparison in healthy human subjects. Psychiatry Res 91 (1999) 79-91
27. Brown J., Lewis V., Brown M., Horn G., and Bowes J.B. A comparison between transient amnesias induced by two drugs (diazepam and lorazepam) and amnesia of organic origin. Neuropsychologia 20 (1982) 55-70
28. Brown M.W., Brown J., and Bowes J.B. Absence of priming coupled with substantially preserved recognition in lorazepam-induced amnesia. Q J Exp Psychol 41A (1989) 599-617
29. Buffet-Jerrott S.E., and Stewart S.H. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des 8 (2002) 45-58
30. Buffett-Jerrott S.E., Stewart S.H., and Teehan M.D. A further examination of the time-dependent effects of oxazepam and lorazepam on implicit and explicit memory. Psychopharmacology 138 (1998) 344-353
31. Buffett-Jerrott S.E., Stewart S.H., Bird S., and Teehan M.D. An examination of differences in the time course of oxazepam's effects on implicit vs explicit memory. J Psychopharmacol 12 (1998) 338-347
32. Carter C.S., Maddock R., Chaderjian M., and Post R. Attentional effects of single dose triazolam. Prog Neuropsychopharmacol 22 (1998) 279-292
33. Chun M.M., and Potter M.C. A two-stage model for multiple target detection in rapid serial visual presentation. J Exp Psychol Hum Percept Perform 21 (1995) 109-127
34. Clarkson J.E., Gordon A.M., and Logan B.K. Lorazepam and driving impairment. J Anal Toxicol 28 (2004) 475-480
35. Cock H.R., and Schapira A.H.V. A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus. QJM 95 (2002) 225-231
36. Conci M., Elliott M.A., Müller H.J., Wendt J., and Becker C. The dynamics of operations in visual memory: A review of conclusions drawn from evidence for oscillatory priming. Exp Psychol 51 (2004) 300-310
37. Conner J.T., Katz R.L., Bellville J.W., Graham C., Pagano R., and Dorey F. Diazepam and lorazepam for intravenous surgical premedication. J Clin Pharmacol 18 (1978) 285-292
38. Curran H.V. Benzodiazepines, memory and mood: A review. Psychopharmacology 105 (1991) 1-8
39. Curran H.V. Memory functions, alertness and mood of long-term benzodiazepine users: a preliminary investigation of the effects of a normal daily dose. J Psychopharmacol 6 (1992) 69-75
40. Curran H.V., and Gorenstein C. Differential effects of lorazepam and oxazepam on priming. Int Clin Psychopharmacol 8 (1993) 37-42
41. Curran H.V., Schiwy W., and Lader M. Differential amnesic properties of benzodiazepines: A dose-response comparison of two drugs with similar elimination half-lives. Psychopharmacology 92 (1987) 358-364
42. Curran H.V., Barrow S., Weingartner H., Lader M., and Bernik M. Encoding, remembering and awareness in lorazepam-induced amnesia. Psychopharmacology 122 (1995) 187-193
43. Dämgen K., and Lüddens H. Zaleplon displays a selectivity torecombinant GABAA receptors different from zolpidem, zopiclone and benzodiazepines. Neurosci Res Commun 25 (1999) 139-148
44. Danion J.M., Peretti S., Grangé D., Bilik M., Imbs J.L., and Singer L. Effects of chlorpromazine and lorazepam on explicit memory, repetition priming and cognitive skill learning in healthy volunteers. Psychopharmacology 108 (1992) 345-351
45. De Winter J., and Wagemans J. The awakening of Attneave's sleeping cat: identification of everyday objects on the basis of straight-line versions of outlines. Perception 37 (2008) 245-270
46. Di Lazzaro V., Oliviero A., Profice P., Pennisi M.A., Di Giovanni S., Zito G., et al. Muscarinic receptor blockade has differential effects on the excitability of intracortical circuits in the human motor cortex. Exp Brain Res 135 (2000) 455-461
47. Di Lazzaro V., Oliviero A., Saturno E., Dileone M., Pilato F., Nardone R., et al. Effects of lorazepam on short latency afferent inhibition and short latency intracortical inhibition in humans. J Physiol 564 (2005) 661-668
48. Di Lazzaro V., Pilato F., Dileone M., Tonali P.A., and Ziemann U. Dissociated effects of diazepam and lorazepam on short-term afferent inhibition. J Physiol 569 (2005) 315-323
49. Duka T., Redemann B., and Voet B. Scopolamine and lorazepam exert different patterns of effects in a test battery assessing stages of information processing. Psychopharmacology 119 (1995) 315-324
50. Dundee J.W., Gowan W.A.W., Lilburn J.K., McKay A.C., and Hegarty J.E. Comparison of the actions of diazepam and lorazepam. Br J Anaesth 51 (1979) 439-446
51. Eckhorn R., Bauer R., Jordan W., Brosch M., Kruse W., Munk M., et al. Coherent oscillations: A mechanism of feature linking in the visual cortex? Multiple electrode and correlation analyses in the cat. Biol Cybern 60 (1988) 121-130
52. Elliott M.A., and Müller H.J. Synchronous information presented in 40-Hz flicker enhances visual feature binding. Psychol Sci 9 (1998) 277-283
53. Elliott M.A., and Müller H.J. Evidence for a 40-Hz oscillatory short-term visual memory revealed by human reaction-time measurements. J Exp Psychol Learn Mem Cogn 26 (2000) 703-718
54. Elliott M.A., and Müller H.J. Effects of stimulus synchrony on mechanisms of perceptual organization. Vis Cogn 8 (2001) 655-677
55. Elliott M.A., Becker C., Boucart M., and Müller H.J. Enhanced GABA(A) inhibition enhances synchrony coding in human perception. NeuroReport 11 (2000) 3403-3407
56. Elliott M.A., Conci M., and Müller H.J. Prefrontal cortex maintains visual information in very short-term oscillatory persistence. Behav Brain Sci 26 (2003) 733-734
57. Elliott M.A., Giersch A., and Seifert D. Some facilitatory effects of lorazepam on dynamic visual binding. Psychopharmacology 184 (2006) 229-238
58. Faulkner H.J., Traub R.D., and Whittington M.A. Disruption of synchronous gamma oscillations in the rat hippocampal slice: a common mechanism of anaesthetic drug action. Br J Pharmacol 125 (1998) 483-492
59. Faulkner H.J., Traub R.D., and Whittington M.A. Anaesthetic/amnesic agents disrupt beta frequency oscillations associated with potentiation of excitatory synaptic potentials in the rat hippocampal slice. Br J Pharmacol 128 (1999) 1813-1825
60. Feshchenko V.A., Veselis R.A., and Reinsel R.A. Comparison of the EEG effects of midazolam, thiopental, and propofol: the role of underlying oscillatory systems. Pharmacoelectroencephalograpy 35 (1997) 211-220
61. Follesa P., Biggio F., Talani G., Murru L., Serra M., Sanna E., et al. Neurosteroids, GABAA receptors, and ethanol dependence. Psychopharmacology 186 (2006) 267-280
62. Frey K.A., Holthoff V.A., Koeppe R.A., Jewett D.M., Kilbourn M.R., and Kuhl D.E. Parametric in vivo imaging of benzodiazepine receptor distribution in human brain. Ann Neurol 30 (1991) 663-672
63. Friston K.J., and Frith C.D. Schizophrenia: A disconnection syndrome?. Clin Neurosci 3 (1995) 89-97
64. Ghoneim M.M., and Mewaldt S.P. Benzodiazepines and human memory: A review. Anesthesiology 72 (1990) 926-938
65. Gibson R.C., and Walcott G. Benzodiazepines for catatonia in people with schizophrenia and other serious mental illnesses. Cochrane Database Syst Rev (2008) CD006570
66. Giersch A. A new pharmacological tool to investigate integration processes. Vis Cogn 6 (1999) 267-297
67. Giersch A. The effects of lorazepam on visual integration processes: How useful for neuroscientists?. Vis Cogn 8 (2001) 549-563
68. Giersch A., and Caparos S. Focused attention is not enough to activate discontinuities in lines, but scrutiny is. Conscious Cogn 14 (2005) 613-632
69. Giersch A., and Fahle M. Modulations of the processing of line discontinuities under selective attention conditions. Percept Psychophys 64 (2002) 67-88
70. Giersch A., and Herzog M. Lorazepam strongly prolongs visual information processing. Neuropsychopharmacology 29 (2004) 1386-1394
71. Giersch A., and Lorenceau J. Effects of a benzodiazepine, lorazepam, on motion integration and segmentation: An effect on the processing of line terminations?. Vis Res 39 (1999) 2017-2025
72. Giersch A., and Vidailhet P. Dissociation between perceptual processing and priming in long-term lorazepam users. Int J Neuropsychopharmacol 9 (2006) 695-704
73. Giersch A., Boucart M., Danion J.M., Vidailhet P., and Legrand F. Effects of lorazepam on perceptual integration of visual forms in healthy volunteers. Psychopharmacology 119 (1995) 105-114
74. Giersch A., Boucart M., Speeg-Schatz C., Muller-Kauffmann F., and Danion J.M. Lorazepam impairs perceptual integration of visual forms: A central effect. Psychopharmacology 126 (1996) 260-270
75. Giersch A., Boucart M., and Danion J.M. Lorazepam, a benzodiazepine, induces atypical distractor effects with compound stimuli: A role for line terminations in the processing of compound letters. Vis Cogn 4 (1997) 337-372
76. Giersch A., Humphreys G.W., Barthaud J.C., and Landmann C. A two-stage account of computing and binding occluded and visible contours: Evidence from visual agnosia and effects of lorazepam. Cogn Neuropsychol 23 (2006) 261-277
77. Giersch A., Speeg-Schatz C., Tondre M., and Gottenkiene S. Impairment of contrast sensitivity in long-term lorazepam users. Psychopharmacology 186 (2006) 594-600
78. Gillies D., Beck A., McCloud A., and Rathbone J. Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis. Cochrane Database Syst Rev (2005) CD003079
79. Goldberg T.E., and Weinberger D.R. A case against subtyping in schizophrenia. Schizophr Res 17 (1995) 147-152
80. Gonzalez-Burgos G., and Lewis D.A. GABA neurons and the mechanisms of network oscillations: Implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull 34 (2008) 944-961
81. Gray C.M. The temporal correlation hypothesis of visual feature integration: Still alive and well. Neuron 24 (1999) 31-47
82. Gray C.M., König P., Engel A.K., and Singer W. Oscillatory responses in cat visual cortex exhibit inter-columnar synchronization which reflects global stimulus properties. Nature 338 (1989) 334-337
83. Greenberg W.M., Triana J.P., and Karajgi B. Lorazepam in the treatment of psychotic symptoms. Am J Psychiatry 143 (1986) 7
84. Greenblatt D.J. Pharmacology of benzodiazepine hypnotics. J Clin Psychiatry 53 S6 (1992) 7-13
85. Greenblatt D.J., Harmatz J.S., Dorsey C., and Shader R.I. Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo. Clin Pharmacol Ther 44 (1988) 326-334
86. Greenblatt D.J., Ehrenberg B.L., Gunderman J., Locniskar A., Scavone J.M., Harmatz, et al. Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. Clin Pharmacol Ther 45 (1989) 356-365
87. Grossberg S. 3-D vision and figure-ground separation by visual cortex. Percept Psychophys 55 (1994) 48-120
88. Healey M., Pickens R., Meisch R., and McKenna T. Effects of clorazepate, diazepam, lorazepam, and placebo on human memory. J Clin Psychiatry 44 (1983) 436-439
89. Henson R.N. Neuroimaging studies of priming. Prog Neurobiol 70 (2003) 53-81
90. Herzog M.H., Fahle M., and Koch C. Spatial aspects of object formation revealed by a new illusion, shine-through. Vis Res 41 (2001) 2325-2335
91. Herzog M.H., Ernst U.A., Etzold A., and Eurich C.W. Local interactions in neural networks explain global effects in the masking of visual stimuli. Neural Comput 15 (2003) 2091-2113
92. Hindmarch I., and Gudgeon A.C. The effects of clobazam and lorazepam on aspects of psychomotor performance and car handling ability. Br J Clin Pharmacol 10 (1980) 145-150
93. Hoffman D.D., and Richards W. Parts of recognition. Cognition 18 (1984) 65-96
94. Horner A.J., and Henson R.N. Priming, response learning and repetition suppression. Neuropsychologia 46 (2008) 1979-1991
95. Huron C., Servais C., and Danion J.M. Lorazepam and diazepam impair true, but not false, recognition in healthy volunteers. Psychopharmacology 155 (2001) 204-209
96. Itil T., Shapiro D., Itil K.Z., Eralp E., Bergamo M., and Mucci A. Discrimination of mode of action of anxiolytics using an integrated computer data bank and dynamic brain mapping (CNS effects of diazepam and lorazepam). Int Clin Psychopharmacol 4 (1989) 273-283
97. Jacoby L.L. A process dissociation framework: separating automatic from intentional uses of memory. J Mem Lang 30 (1991) 513-541
98. Jalava K.M., Mattila M.J., Tarssanen M., and Vanakoski J. Lorazepam and diazepam differently impair attention. Pharmacol Biochem Behav 51 (1995) 189-197
99. Jaspert A., and Ebert D. Benzodiazepine monotherapy in acute schizophrenia. Nervenarzt 65 (1994) 62-65
100. Johnson D.N., Weingartner H.J., Andreason P., and George D.T. An effect of triazolam on visual attention and information processing. Psychopharmacology 121 (1995) 145-149
101. Kaila K. Ionic basis of GABAA receptor channel function in the nervous system. Prog Neurobiol 42 (1994) 489-537
102. Kane J.M. Schizophrenia. New Engl J Med 334 (1996) 34-41
103. Knopman D. Unaware learning versus preserved learning in pharmacologic amnesia: Similarities and differences. J Exp Psychol Learn Mem Cogn 17 (1991) 1017-1029
104. Kothary S.P., Brown A.C.D., Pandit U.A., Samra S.K., and Pandit S.K. Time course of antirecall effect of diazepam and lorazepam following oral administration. Anesthesiology 55 (1981) 641-644
105. Kovacs I., Kozma P., Feher A., and Benedek G. Late maturation of visual spatial integration in humans. Proc Natl Acad Sci 96 (1999) 12204-12209
106. Kujirai T., Caramia M.D., Rothwell J.C., Day B.L., Thompson P.D., Ferbert A., et al. Corticocortical inhibition in human motor cortex. J Physiol 471 (1993) 501-519
107. Kumar R., Mac D.S., Gabrielli Jr. W.F., and Goodwin D.W. Anxiolytics and memory: a comparison of lorazepam and alprazolam. J Clin Psychiatry 48 (1987) 158-160
108. Lamote C., and Wagemans J. Rapid integration of contour elements: From simple filling-in to parts-based shape description. Vis Cogn 6 (1999) 345-361
109. Legrand F., Vidailhet P., Danion J.M., Grangé D., Giersch A., Van Der Linden M., et al. Time course of the effects of diazepam and lorazepam on perceptual priming and explicit memory. Psychopharmacology 118 (1995) 475-479
110. Leppik I.E., Derivan A.T., Homan R.W., Walker J., Ramsay R.E., and Patrick B. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 249 (1983) 1452-1454
111. Leventhal A.G., Wang Y., Pu M., Zhou Y., and Ma Y. GABA and its agonists improved visual function in senescent monkeys. Science 300 (2003) 812-815
112. Lingjaerde O. Benzodiazepines in the treatment of schizophrenia: an updated survey. Acta Psychiatr Scand 84 (1991) 453-459
113. Link C.G., Leigh T.J., and Fell G.L. Effects of graniseton and lorazepam, alone and in combination, on the EEG of human volunteers. Br J Clin Pharmacol 31 (1991) 93-97
114. Lorenceau J., Giersch A., and Seriès P. Dynamic competition between contour integration and contour segmentation probed with moving stimuli. Vis Res 45 (2005) 103-116
115. Lüdtke H., Wilhelm M., Adler F., Schaeffel H., and Wilhelm H. Mathematical procedures in data recording and processing of pupillary fatigue waves. Vis Res 38 (1998) 2889-2996
116. Mandema J.W., Kuck M.T., and Danhof M. Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship. Br J Pharmacol 105 (1992) 162-170
117. Martin J., Matthews A., Martin F., Kirkby K.C., Alexander J., and Daniels B. Effects of lorazepam and oxazepam on perceptual and procedural memory functions. Psychopharmacology 164 (2002) 262-267
118. Matthew E., Andreason P., Pettigrew K., Carson R.E., Herscovitch P., Cohen R., et al. Benzodiazepine receptors mediate regional blood flow changes in the living human brain. Proc Natl Acad Sci USA 92 (1995) 2775-2779
119. A-receptor subtypes really occur in the brain?. TINS 19 (1996) 139-143
120. Mendelson W.B., Thompson C., and Franko T. Adverse reactions to sedative/hypnotics: Three years' experience. Sleep 19 (1996) 702-706
121. Mintzer M.Z., and Griffiths R.R. Triazolam and zolpidem: Effects on human memory and attentional processes. Psychopharmacology 144 (1999) 8-19
122. Mintzer M.Z., and Griffiths R.R. Lorazepam and scopolamine: A single-dose comparison of effects on human memory and attentional processes. Exp Clin Psychopharmacol 11 (2003) 56-72
123. Möhler H. Molecular regulation of cognitive functions and developmental plasticity: Impact of GABAA receptors. J Neurochem 102 (2007) 1-12
124. Nakayama K., Shimojo S., and Silverman G.H. Stereoscopic depth: Its relation to image segmentation, grouping, and the recognition of occluded objects. Perception 18 (1989) 55-68
125. Nordberg A., and Wahlström G. Cholinergic mechanisms in physical dependence on barbiturates, ethanol and benzodiazepines. J Neural Transm Gen Sect 88 (1992) 199-221
126. O'Hanlon J.F., Vermeeren A., Uiterwijk M.M., van Veggel L.M., and Swijgman H.F. Anxiolytics' effects on the actual driving performance of patients and healthy volunteers in a standardized test. An integration of three studies. Neuropsychobiology 31 (1995) 81-88
127. Olsen R.W., and Sieghart W. GABAA receptors: Subtypes provide diversity of function and pharmacology. Neuropharmacology 56 (2009) 141-148
128. Patat A., Klein M.J., and Hucher M. Effects of single oral doses of clobazam, diazepam and lorazepam on performance tasks and memory. Eur J Clin Pharmacol 32 (1987) 461-466
129. Paton C., Banham S., and Whitmore J. Benzodiazepines in schizophrenia. Is there a trend towards long-term prescribing?. Psychiatr Bull 24 (2000) 113-115
130. Pecknold J.C. Survey of the adjuvant use of benzodiazepines for treating out-patients with schizophrenia. J Psychiatry Neurosci 18 (1993) 82-84
131. Pickar D., Vinik J., and Bartko J.J. Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use. PloSOne 3 (2008) e3150
132. Pomara N., Tun H., DaSilva D., Hernando R., Deptula D., and Greenblatt D.J. The acute and chronic performance effects of alprazolam and lorazepam in the elderly: Relationship to duration of treatment and self-rated sedation. Psychopharmacol Bull 34 (1998) 139-153
133. Pomara N., Willoughby L.M., Ritchie J.C., Sidtis J.J., Greenblatt D.J., and Nemeroff C.B. Interdose elevation in plasma cortisol during chronic treatment with alprazolam but not lorazepam in the elderly. Neuropsychopharmacology 29 (2004) 605-611
134. Pompéia S., Bueno O.F., Lucchesi L.M., Manzano G.M., Galduróz J.C., and Tufik S. A double-dissociation of behavioural and event-related potential effects of two benzodiazepines with similar potencies. J Psychopharmacol 14 (2000) 288-298
135. Pompéia S., Bueno O.F., Galduroz J.C., and Tufik S. Stem-completion tasks (indirect, direct inclusion and exclusion) are differently affected by equipotent doses of lorazepam and flunitrazepam. Hum Psychopharmacol 18 (2003) 541-549
136. Pompéia S., Bueno O.F., and Tufik S. Lorazepam should no longer be used as a prototypical benzodiazepine. Psychopharmacology 169 (2003) 211-212
137. Pompéia S., Manzano G.M., Tufik S., and Bueno O.F.A. What makes lorazepam different from other benzodiazepines?. J Physiol 569 (2005) 709
138. Post R.B., Chaderjian M.R., Lott L.A., and Maddock R.J. Effects of lorazepam on the distribution of spatial attention. Exp Clin Psychopharmacol 5 (1997) 143-149
139. Qureshi A., Wassmer E., Davies P., Berry K., and Whitehouse W.P. Comparative audit of intravenous lorazepam and diazepam in the emergency treatment of convulsive status epilepticus in children. Seizure 11 (2002) 141-144
140. Raymond J.E., Shapiro K.L., and Arnell K.M. Temporary suppression of visual processing in an RSVP task: an attentional blink?. J Exp Psychol Hum Percept Perform 18 (1992) 849-860
141. Reilly J.L., Lencer R., Bishop J.R., Keedy S., and Sweeney J.A. Pharmacological treatment effects on eye movement control. Brain Cogn 68 (2008) 415-435
142. Roach B.J., and Mathalon D.H. Event-related EEG time-frequency analysis: An overview of measures and an analysis of early gamma band phase locking in schizophrenia. Schizophr Bull 34 (2008) 907-926
143. Roediger H.L.I.I.I., and Challis B.H. Effects of exact repetition and conceptual repetition on free recall and primed word-fragment completion. J Exp Psychol Learn Mem Cogn 18 (1992) 3-14
144. Roelofse J.A., and van der Bijl P. Cardiac dysrhythmias associated with intravenous lorazepam, diazepam, and midazolam during oral surgery. J Oral Maxillofac Surg 52 (1994) 247-250
145. Saletu B., and Grünberger J. Evaluation of pharmacodynamic properties of psychotropic drugs: Quantitative EEG, psychometric and blood level investigations in normals and patients. Pharmakopsychiatr Neuropsychopharmakol 12 (1979) 45-58
146. Sannerud C.A., and Ator N.A. Drug discrimination analysis of midazolam under a three-lever procedure II: differential effects of benzodiazepine receptor agonists. J Pharmacol Exp Ther 276 (1995) 183-193
147. Schacter D.L., Wig G.S., and Stevens W.D. Reduction in cortical activity during priming. Curr Opin Neurobiol 17 (2007) 171-176
148. Schaeffel F., Wilhelm H., and Zrenner E. Inter-individual variability in the dynamics of natural accommodation in humans: Relation to age and refractive errors. J Physiol 461 (1993) 301-320
149. Schmider J., Standhart H., Deuschle M., Drancoli J., and Heuser I. A double-blind comparison of lorazepam and oxazepam in psychomotor retardation and mutism. Biol Psychiatry 46 (1999) 437-441
150. Seethalakshmi R., Dhavale S., Suggu K., and Dewan M. Catatonic syndrome: importance of detection and treatment with lorazepam. Ann Clin Psychiatry 20 (2008) 5-8
151. Sellal F., Danion J.M., Kauffmann-Muller F., Grangé D., Imbs J.L., Van Der Linden M., et al. Differential effects of diazepam and lorazepam on repetition priming in healthy volunteers. Psychopharmacology 108 (1992) 371-379
152. Singer W. Neuronal synchrony: A versatile code for the definition of relations?. Neuron 24 (1999) 49-65
153. Stewart S.A. The effects of benzodiazepines on cognition. J Clin Psychiatry 66 suppl 2 (2005) 9-13
154. Stewart S.H., Rioux G.F., Connolly J.F., Dunphy S.C., and Teehan M.D. Effects of oxazepam and lorazepam on implicit and explicit memory: Evidence for possible influences of time course. Psychopharmacology 128 (1996) 139-149
155. Stoner G.R., Albright T.D., and Ramachandran V.S. Transparency and coherence in human motion perception. Nature 344 (1990) 153-155
156. Thiel C.M., Henson R.N., Morris J.S., Friston K.J., and Dolan R.J. Pharmacological modulation of behavioral and neuronal correlates of repetition priming. J Neurosci 21 (2001) 6846-6852
157. Tokimura H., Di Lazzaro V., Tokimura Y., Oliviero A., Profice P., Insola A., et al. Short latency inhibition of human hand motor cortex by somatosensory input from the hand. J Physiol 523 (2000) 503-513
158. Tononi G., and Edelman G.M. Schizophrenia and the mechanisms of conscious integration. Brain Res Rev 31 (2000) 391-400
159. Tulen J.H., and Man in't Veld A.J. Noninvasive indices of autonomic regulation after alprazolam and lorazepam: Effects on sympathovagal balance. J Cardiovasc Pharmacol 32 (1998) 183-190
160. Tulving E., and Schacter D.L. Priming and human memory systems. Science 247 (1990) 301-306
161. Uhlhaas P.J., Haenschel C., Nikolic D., and Singer W. The role of oscillations and synchrony in cortical networks and their putative relevance for the pathophysiology of schizophrenia. Schizophr Bull 34 (2008) 927-943
162. van den Berg F., Tulen J.H., Boomsma F., Noten J.B., Moleman P., and Pepplinkhuizen L. Effects of alprazolam and lorazepam on catecholaminergic and cardiovascular activity during supine rest, mental load and orthostatic challenge. Psychopharmacology 128 (1996) 21-30
163. Vidailhet P., Danion J.M., Kauffman-Muller F., Grangé D., Giersch A., Van Der Linden, et al. Lorazepam and diazepam effects on memory acquisition in priming tasks. Psychopharmacology 115 (1994) 397-406
164. Vidailhet P., Kazès M., Danion J.M., Kauffmann-Muller F., and Grangé D. Effects of lorazepam and diazepam on conscious and automatic memory processes. Psychopharmacology 127 (1996) 63-72
165. Vidailhet P., Danion J.M., Chemin C., and Kazès M. Lorazepam impairs both visual and auditory perceptual priming. Psychopharmacology 147 (1999) 266-273
166. Volz A., Khorsand V., Gillies D., and Leucht S. Benzodiazepines for schizophrenia. Cochrane Data Base Syst Rev (2007) CD006391
167. Von der Heydt R., and Peterhans E. Mechanisms of contour perception in monkey visual cortex 1: lines of pattern discontinuities. J Neurosci 9 (1989) 1731-1748
168. Wagemans J., Notebaert W., and Boucart M. Lorazepam but not diazepam impairs identification of pictures on the basis of specific contour fragments. Psychopharmacology 138 (1998) 326-333
169. Wang G.J., Volkow N.D., Overall J., Hitzemann R.J., Pappas N., Pascani K., et al. Reproducibility of regional brain metabolic responses to lorazepam. J Nucl Med 37 (1996) 1609-1613
170. Whiting P.J. GABA-A receptors: A viable target for novel anxiolytics?. Curr Opin Pharmacol 6 (2006) 24-29
171. Whittington M.A., Traub R.D., Faulkner H.J., Stanford I.M., and Jefferys J.G.R. Recurrent excitatory post-synaptic potentials induced by synchronised fast cortical oscillations. Proc Natl Acad Sci USA 94 (1997) 12198-12203
172. Whittington M.A., Traub R.D., Kopell N., Ermentrout B., and Buhl E.H. Inhibition-based rhythms: Experimental and mathematical observations on network dynamics. Int J Psychophysiol 38 (2000) 315-336
173. Whittington M.A., Doheny H.C., Traub R.D., LeBeau F.E., and Buhl E.H. Differential expression of synaptic and nonsynaptic mechanisms underlying stimulus-induced gamma oscillations in vitro. J Neurosci 21 (2001) 1727-1738
174. Wolkowitz O.M., and Pickar D. Benzodiazepines in the treatment of schizophrenia: A review and reappraisal. Am J Psychiatry 148 (1991) 714-726
175. Ziemann U., Lonnecker S., Steinhof B.J., and Paulus W. Effects of antiepileptic drugs on motor excitability in humans: A transcranial magnetic stimulation study. Ann Neurol 40 (1996) 367-378